Lydia Gorski, MD
Internal Medicine · New Hyde Park, NYNPI 1376602201
Payments from drug & device makers
Across 635 payments — averaging $28.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- AstraZeneca$2K
- GSK$2K
- Astellas Pharma US Inc$2K
- AbbVie$1K
- Abbott$935
- plus $7K from 31 others
What the payments were for
- Food & beverage$17,54696%
- Education$6694%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 91 | $3,734 |
| AstraZeneca | 64 | $2,305 |
| GSK | 56 | $1,706 |
| Astellas Pharma US Inc | 51 | $1,514 |
| AbbVie(2 entities) | 57 | $1,210 |
| Abbott | 26 | $935 |
| Amarin Pharma, Inc. | 49 | $857 |
| Esperion Therapeutics, Inc. | 29 | $763 |
| Boehringer Ingelheim | 29 | $563 |
| Pfizer | 39 | $546 |
| Johnson & Johnson | 21 | $496 |
| E.r. Squibb & Sons, L.L.C. | 7 | $439 |
| Otsuka America Pharmaceutical, Inc. | 9 | $376 |
| Kowa Pharmaceuticals America, Inc. | 18 | $307 |
| Novartis | 15 | $303 |
| Medicure Pharma Inc. | 1 | $300 |
| Merck | 8 | $200 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $181 |
| Lilly USA, LLC | 8 | $167 |
| Sumitomo Pharma America, Inc. | 5 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $129 |
| Eisai Inc. | 1 | $125 |
| Novo Nordisk | 5 | $116 |
| Amneal Pharmaceuticals LLC | 7 | $114 |
| Alfasigma USA, Inc. | 6 | $108 |
| Medtronic | 1 | $108 |
| SK Life Science, Inc. | 1 | $106 |
| Bayer | 3 | $81 |
| Exact Sciences | 3 | $62 |
| Biohaven Pharmaceuticals, Inc. | 2 | $47 |
| SPR Therapeutics, Inc | 1 | $34 |
| Genentech USA, Inc. | 2 | $27 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Dermira, Inc. | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Intuity Medical Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,215 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 62 | $94,719 |
| FarxigaDapagliflozin Propanediol | 55 | $74,497 |
| Repatha SureclickEvolocumab | 44 | $56,114 |
| TradjentaLinagliptin | 23 | $31,518 |
| XareltoRivaroxaban | 24 | $29,375 |
| JanuviaSitagliptin Phosphate | 23 | $27,660 |
| OzempicSemaglutide | 20 | $21,975 |
| JardianceEmpagliflozin | 14 | $18,918 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $15,992 |
| SynthroidLevothyroxine Sodium | 176 | $13,645 |
| VascepaIcosapent Ethyl | 13 | $10,702 |
| MyrbetriqMirabegron | 16 | $9,728 |
| LivaloPitavastatin Calcium | 11 | $9,166 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $8,702 |
| Pitavastatin Calcium | 35 | $6,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $546 | $94,71962 claims |
| AstraZenecaFarxiga | $2,305 | $74,49755 claims |
| Boehringer IngelheimTradjenta, Jardiance | $563 | $50,43637 claims |
| Johnson & JohnsonXarelto | $496 | $29,37524 claims |
| MerckJanuvia | $200 | $27,66023 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,706 | $24,69428 claims |
| Novo NordiskOzempic | $116 | $21,97520 claims |
| AbbVieSynthroid | $1,210 | $13,645176 claims |
| Astellas Pharma US IncMyrbetriq | $1,514 | $9,72816 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $307 | $9,16611 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $114 | $4,144372 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New Hyde Park
- Nagashree SeetharamuNew Hyde Park$2.5M
- Janice WangNew Hyde Park$2.1M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.